Biblio

Found 47 results
Filters: Author is Brinton, Roberta Diaz  [Clear All Filters]
2022
Branigan GL, Torrandell-Haro G, Vitali F, Brinton RDiaz, Rodgers K.  2022.  Age and sex differences on anti-hyperglycemic medication exposure and risk of newly diagnosed multiple sclerosis in propensity score matched type 2 diabetics.. Heliyon. 8(10):e11196.
Branigan GL, Torrandell-Haro G, Soto M, Gelmann EP, Vitali F, Rodgers KE, Brinton RDiaz.  2022.  Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer.. Cancer Med. 11(13):2687-2698.
Torrandell-Haro G, Branigan GL, Brinton RDiaz, Rodgers KE.  2022.  Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer's Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic Patients.. Front Aging Neurosci. 14:878304.
McLean JW, Bhattrai A, Vitali F, Raikes AC, Wiegand J-PL, Brinton RDiaz.  2022.  Contributions of sex and genotype to exploratory behavior differences in an aged humanized mouse model of late-onset Alzheimer's disease.. Learn Mem. 29(9):321-331.
Tang X, Brinton RDiaz, Chen Z, Farland LV, Klimentidis Y, Migrino R, Reaven P, Rodgers K, Zhou JJ.  2022.  Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes.. BMJ Open Diabetes Res Care. 10(5)
2021
Qi G, Mi Y, Shi X, Gu H, Brinton RDiaz, Yin F.  2021.  ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism.. Cell Rep. 34(1):108572.
Mi Y, Qi G, Brinton RDiaz, Yin F.  2021.  Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential.. Antioxid Redox Signal. 34(8):611-630.
2017
Geifman N, Brinton RDiaz, Kennedy RE, Schneider LS, Butte AJ.  2017.  Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease.. Alzheimers Res Ther. 9(1):10.
Zissimopoulos JM, Barthold D, Brinton RDiaz, Joyce G.  2017.  Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease.. JAMA Neurol. 74(2):225-232.
Mosconi L, Berti V, Quinn C, McHugh P, Petrongolo G, Varsavsky I, Osorio RS, Pupi A, Vallabhajosula S, Isaacson RS et al..  2017.  Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging.. Neurology. 89(13):1382-1390.
2016
Rettberg JR, Dang H, Hodis HN, Henderson VW, St John JA, Mack WJ, Brinton RDiaz.  2016.  Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype.. Neurobiol Aging. 40:155-63.
Brinton RDiaz.  2016.  Neuroendocrinology: Oestrogen therapy affects brain structure but not function.. Nat Rev Neurol. 12(10):561-2.
2015
Espeland MA, Brinton RDiaz, Hugenschmidt C, Manson JAE, Craft S, Yaffe K, Weitlauf J, Vaughan L, Johnson KC, Padula CB et al..  2015.  Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women.. Diabetes Care. 38(12):2316-24.
Espeland MA, Brinton RDiaz, Manson JAE, Yaffe K, Hugenschmidt C, Vaughan L, Craft S, Edwards BJ, Casanova R, Masaki K et al..  2015.  Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes.. Neurology. 85(13):1131-8.
Caldwell CC, Yao J, Brinton RDiaz.  2015.  Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities.. Neurotherapeutics. 12(1):66-80.
Klosinski LP, Yao J, Yin F, Fonteh AN, Harrington MG, Christensen TA, Trushina E, Brinton RDiaz.  2015.  White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease.. EBioMedicine. 2(12):1888-904.
2014
Rettberg JR, Yao J, Brinton RDiaz.  2014.  Estrogen: a master regulator of bioenergetic systems in the brain and body.. Front Neuroendocrinol. 35(1):8-30.
Irwin RW, Solinsky CM, Brinton RDiaz.  2014.  Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders.. Front Cell Neurosci. 8:203.
2013
Ding F, Yao J, Rettberg JR, Chen S, Brinton RDiaz.  2013.  Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention.. PLoS One. 8(11):e79977.
Ding F, Yao J, Zhao L, Mao Z, Chen S, Brinton RDiaz.  2013.  Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer's.. PLoS One. 8(3):e59825.
Yao J, Zhao L, Mao Z, Chen S, Wong KCarmen, To J, Brinton RDiaz.  2013.  Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor β-selective phytoSERM treatments.. Brain Res. 1514:128-41.
Singh M, Simpkins JW, Simpkins JW, Bimonte-Nelson HA, Bimonte-Nelson HA, Brinton RDiaz.  2013.  Window of opportunity for estrogen and progestin intervention in brain aging and Alzheimer's disease.. Brain Res. 1514:1-2.
2012
Jayaraman A, Carroll JC, Morgan TE, Lin S, Zhao L, Arimoto JM, M Murphy P, Beckett TL, Finch CE, Brinton RDiaz et al..  2012.  17β-estradiol and progesterone regulate expression of β-amyloid clearance factors in primary neuron cultures and female rat brain.. Endocrinology. 153(11):5467-79.
Wang JMing, Hou X, Adeosun S, Hill R, Henry S, Paul I, Irwin RW, Ou X-M, Bigler S, Stockmeier C et al..  2012.  A dominant negative ERβ splice variant determines the effectiveness of early or late estrogen therapy after ovariectomy in rats.. PLoS One. 7(3):e33493.
Yao J, Brinton RDiaz.  2012.  Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.. Adv Pharmacol. 64:327-71.

Pages